Login to Your Account



Stock sales yield $47M for Shield Therapeutics, $30M for Karo Bio

By Cormac Sheridan
Staff Writer

Friday, February 12, 2016

DUBLIN – European biopharmas have made a sleepy start to the new year, but with spring on the way, two transactions unveiled Friday could be harbingers of more activity to come. The scale is modest. Shield Therapeutics Ltd. took in £32.5 million (US$47 million) and Karo Bio AB, meanwhile, will gross SEK250 million (US$29.6 million) in a discounted share offering.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription